Tech Company Financing Transactions
Vanqua Bio Funding Round
On 9/15/2021, Vanqua Bio received $85 million in Series B funding from Omega Funds, Avoro Capital Advisors and Casdin Capital.
Transaction Overview
Company Name
Announced On
9/15/2021
Transaction Type
Venture Equity
Amount
$85,000,000
Round
Series B
Investors
Omega Funds (Lead Investor) (Bernard Davitian)
Avoro Capital Advisors (Sara Nayeem)
OrbiMed (Jonathan Silverstein)
Proceeds Purpose
Proceeds from the financing will be used to accelerate the development of the company's innovative therapeutic programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2430 N Halsted St. 110
Chicago, IL 60614
USA
Chicago, IL 60614
USA
Phone
Undisclosed
Website
Email Address
Overview
Vanqua Bio is helping usher in a new era of hope for patients living with neurodegenerative disorders. Toward that end, we have assembled a world-class team of scientists, board members, and advisors with proven capabilities in advancing molecules that become transformative medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Sullivan
Chief Financial Officer
Viola Meehan
Chief Scientific Officer
Kevin Hunt
VP - Bus. Development
Jack Beyer
Browse more venture capital transactions:
Prev: 9/15/2021: Sproutt venture capital transaction
Next: 9/15/2021: Versatile venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs